You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

FGFR3 gene fusion/rearrangement

Showing 1 - 25 of 7,673
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement Trial (TAS-120)

Not yet recruiting
  • Advanced Cholangiocarcinoma
  • +2 more
  • (no location specified)
Feb 3, 2023

Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression Trial in Worldwide (Data collection and quality of life

Recruiting
  • Cancer
  • +15 more
  • Data collection and quality of life questionnaire
  • Graz, Austria
  • +40 more
Jul 27, 2021

Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor Trial (TYRA-300)

Not yet recruiting
  • Locally Advanced Urothelial Carcinoma
  • +3 more
  • (no location specified)
Sep 15, 2022

Solid Tumor, FGF Receptor Gene Mutation, FGF Amplification Trial in Tianjin (Pemigatinib)

Recruiting
  • Solid Tumor
  • +4 more
  • Tianjin, Tianjin, China
    Tianjin Medical University Second Hospital
Aug 28, 2023

Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma Trial (Biospecimen Collection,

Not yet recruiting
  • Recurrent Glioblastoma, IDH-Wildtype
  • +2 more
  • Biospecimen Collection
  • +2 more
  • (no location specified)
May 13, 2023

Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma Trial in Taiwan, United States (KIN-3248)

Recruiting
  • Solid Tumor, Adult
  • +2 more
  • La Jolla, California
  • +4 more
Aug 9, 2022

FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR1 Gene Translocation Trial in United States (Pemigatinib, Quality-of-Life

Active, not recruiting
  • FGFR1 Gene Amplification
  • +18 more
  • Scottsdale, Arizona
  • +5 more
Oct 18, 2022

Urinary Bladder Tumors, Tumor Metastasis, Ureteral Tumors Trial in New York, Myrtle Beach, Nashville (LOXO-435, Pembrolizumab)

Recruiting
  • Urinary Bladder Neoplasms
  • +2 more
  • New York, New York
  • +2 more
Jan 31, 2023

Bladder Cancer, Recurrent Bladder Cancer, FGFR3 Gene Mutation Trial in United States (Erdafitinib)

Recruiting
  • Bladder Cancer
  • +2 more
  • Basking Ridge, New Jersey
  • +6 more
Aug 22, 2022

NSCLC, Pancreatic Cancer, Locally Advanced Solid Tumor Trial in Sydney (HMBD-001, Docetaxel, Nab-paclitaxel)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • +3 more
  • Sydney, New South Wales, Australia
    GenesisCare North Shore
Jun 16, 2023

Intrahepatic Cholangiocarcinoma, Combined Hepatocellular and Cholangiocarcinoma Trial in Worldwide (derazantinib)

Recruiting
  • Intrahepatic Cholangiocarcinoma
  • Combined Hepatocellular and Cholangiocarcinoma
  • Phoenix, Arizona
  • +40 more
Mar 7, 2022

Advanced Malignant Solid Tumor, Cholangiocarcinoma, Metastatic Malignant Solid Tumor Trial in Columbus (Infigratinib)

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 15, 2022

Solid Tumor Trial in Worldwide (Debio 1347)

Terminated
  • Solid Tumor
  • Debio 1347
  • Scottsdale, Arizona
  • +104 more
Mar 30, 2022

Cholangiocarcinoma, FGFR2 Fusion, FGFR2 Gene Mutation Trial in United States (TT-00420)

Recruiting
  • Cholangiocarcinoma
  • +4 more
  • Anchorage, Alaska
  • +16 more
Jan 3, 2023

Clear Cell Sarcoma Trial in El Segundo, Houston (AMG 337)

Terminated
  • Clear Cell Sarcoma
  • AMG 337
  • El Segundo, California
  • +1 more
Dec 9, 2022

NSCLC Trial in Suzhou (Pemigatinib)

Recruiting
  • Non-Small Cell Lung Cancer
  • Suzhou, China
    The First Affiliated Hospital of Soochow University
Jan 14, 2022

Cholangiocarcinoma Trial in China, Japan (E7090)

Active, not recruiting
  • Cholangiocarcinoma
  • Bengbu, Anhui, China
  • +55 more
Jan 24, 2023

Solid Tumor Trial in Italy, United States (Derazantinib low dose range, Derazantinib middle dose range, Derazantinib high dose

Completed
Has Results
  • Solid Tumor
  • Derazantinib low dose range
  • +3 more
  • Scottsdale, Arizona
  • +11 more
Mar 7, 2022

MPN (Myeloproliferative Tumors) Trial in Worldwide (Pemigatinib)

Active, not recruiting
  • MPN (Myeloproliferative Neoplasms)
  • Phoenix, Arizona
  • +32 more
Jun 24, 2022

NTRK Family Gene Mutation Trial in Germany

Recruiting
  • NTRK Family Gene Mutation
    • Berlin, Germany
    • +22 more
    Jan 18, 2023

    Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib

    Recruiting
    • Bladder Cancer
    • +12 more
    • Raleigh, North Carolina
      xCures Virtual Site
    Sep 20, 2021

    Advanced Cholangiocarcinoma, FGFR2 Gene Rearrangements Trial in Worldwide (TAS-120, Cisplatin/Gemcitabine)

    Active, not recruiting
    • Advanced Cholangiocarcinoma
    • FGFR2 Gene Rearrangements
    • Albuquerque, New Mexico
    • +100 more
    Feb 1, 2023

    NSCLC Stage IIIB, NSCLC Stage IV, EGFR Gene Mutation Trial in France (Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab,

    Recruiting
    • NSCLC Stage IIIB
    • +4 more
    • Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab
    • Carboplatin + Pemetrexed + Atezolizumab
    • Angers, France
    • +30 more
    Jun 7, 2021

    Cholangiocarcinoma,Adult Trial (3D185)

    Not yet recruiting
    • Cholangiocarcinoma,Adult
    • (no location specified)
    Sep 2, 2021

    Circulating Tumor DNA-Guided Late-Line Treatment in Late-Stage

    Completed
    • Metastatic Breast Cancer
    • +2 more
    • Control group
    • Case group
    • (no location specified)
    Jun 16, 2022